Phaseline

Targets › DPP4

DPP4 (Dipeptidyl peptidase 4): drug programs, companies and trials

19 programs from 18 companies in 30 trials: 12 Phase 3, 9 Phase 1, 5 Phase 4, 4 Phase 2; Metabolic and endocrine, Oncology, Cardiovascular; next expected readout Nov 2026.

Cell surface glycoprotein receptor involved in the costimulatory signal essential for T-cell receptor (TCR)-mediated T-cell activation. Acts as a positive regulator of T-cell coactivation, by binding at least ADA, CAV1, IGF2R, and PTPRC. Its binding to CAV1 and CARD11 induces T-cell proliferation and NF-kappa-B activation in a T-cell receptor/CD3-dependent manner. (UniProt, P27487)

Open in Phaseline: the race on DPP4, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Huazhong University of Science and TechnologyCofrogliptin
DPP-4 inhibitor
DPP4Phase 4T2DMDec 2026
JW PharmaceuticalAnagliptin
Dipeptidyl peptidase IV inhibitor
DPP4Phase 4Type 2 Diabetes Mellitus (T2DM)Mar 2027
Tanta UniversitySitagliptin
Dipeptidyl peptidase IV inhibitor
DPP4Phase 4Breast CancerNov 2027
Nabiqasim Industries (Pvt)Linagliptin
Dipeptidyl peptidase IV inhibitor
DPP4Phase 4Diabetes Mellitus–
University of PennsylvaniaSitagliptin
Dipeptidyl peptidase IV inhibitor
DPP4Phase 4Genetics Disease–
CSPC Ouyi PharmaceuticalPrusogliptin
Dipeptidyl peptidase-4 inhibitor
DPP4Phase 3Type 2 DiabetesNov 2026
AstraZenecaElecoglipron
Dipeptidyl peptidase-4 (DPP-4) inhibitor
DPP4, GCK, GCGRPhase 3Obesity; Type 2 Diabetes Mellitus; Weight Management; Heart Failure With Preserved Ejection Fraction (HFpEF) …Nov 2026
Sherief Abd-ElsalamVildagliptin
Dipeptidyl peptidase IV inhibitor
DPP4Phase 3dmDec 2028
Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB ChairSaxagliptin Hydrochloride
Dipeptidyl peptidase IV inhibitor
DPP4Phase 2Type 2 DiabetesNov 2026
Case Comprehensive Cancer CenterSitagliptin
Dipeptidyl peptidase IV inhibitor
DPP4Phase 2GlioblastomaJun 2027
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversitySitagliptin
Dipeptidyl peptidase IV inhibitor
DPP4Phase 2Bladder Urothelial CarcinomaJun 2028
October 6 UniversityVildagliptin
Dipeptidyl peptidase IV inhibitor
DPP4Phase 2Poly Cystic Ovary Syndrome–
Eric Stephen Winer, MDBXCL701
Dipeptidyl peptidase-4 (DPP4) inhibitor
DPP4Phase 1Acute Myeloid LeukemiaDec 2026
Fernando Maciel BarbosaSitagliptin
Dipeptidyl peptidase IV inhibitor
DPP4Phase 1Advanced Renal Cell CarcinomaApr 2028
Kailin Yang, MD, PhDSitagliptin
Dipeptidyl peptidase IV inhibitor
DPP4Phase 1GliomaJun 2029
Second Affiliated Hospital, Zhejiang University, School of MedicineSitagliptin
Dipeptidyl peptidase IV inhibitor
DPP4Phase 1Colorectal CancerDec 2029
Northwell HealthSitagliptin
Dipeptidyl peptidase IV inhibitor
DPP4Phase 1GVHD - Graft-Versus-Host DiseaseJul 2030
University of Yaounde 1Cissus quadrangularis extract (CQE)
DPP-4 inhibition and GLP-1 elevation
DPP4Phase 1Obesity and Overweight–
University of Yaounde 1Dichrostachys glomerata extract (DGE)
DPP-4 inhibition and GLP-1 elevation
DPP4Phase 1Obesity and Overweight–

Conditions

Type 2 Diabetes Mellitus (5) Healthy Participants (2) Type 2 Diabetes (2) dm (2) Obesity and Overweight (2) Poly Cystic Ovary Syndrome (1) Glioblastoma (1) Obesity (1) Weight Management (1) Heart Failure With Preserved Ejection Fraction (HFpEF) (1) Chronic Kidney Disease (1) Glioma (1)

Modalities

small molecule (12), mixed (6)

Companies

University of Yaounde 1 (2) October 6 University (1) Case Comprehensive Cancer Center (1) AstraZeneca (1) Kailin Yang, MD, PhD (1) Eric Stephen Winer, MD (1) CSPC Ouyi Pharmaceutical (1) Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair (1) Nabiqasim Industries (Pvt) (1) Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1) Sherief Abd-Elsalam (1) Tanta University (1) Huazhong University of Science and Technology (1) Second Affiliated Hospital, Zhejiang University, School of Medicine (1) University of Pennsylvania (1) Northwell Health (1) JW Pharmaceutical (1) Fernando Maciel Barbosa (1)

Related targets

GCK (1) GCGR (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.